.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2014 for a monstrous $43...
.On the heels of a stage 3 win that stopped working to make an impression on entrepreneurs, Ironwood...
.Don't quit Monte Rosa Therapeutics currently. The Boston-based biotech is actually enjoying after s...
.Invite to this week's Chutes & Ladders, our summary of notable leadership hirings, firings and a...
.Commemorating his business's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has gone back to the resource of its own antipsychotic giant Vraylar looking for one more bl...
.GenSight Biologics is weeks far from lacking money. Again. The biotech simply has enough money to f...
.Monopar Therapeutics is actually bouncing back a medicine coming from the scrap heap of AstraZeneca...
.Along with brand-new information out on Arcus Biosciences' experimental HIF-2a inhibitor, one group...
.After forming a genetics treatment partnership with Dyno Rehabs in 2020, Roche is back for more.In ...
.Lundbeck is actually slashing the book market value of its own $250 million Abide Rehabs acquistion...
.The assimilation of real-world records (RWD) in to procedure workability and also internet site var...
.At this year's Tough Biotech Summit in Boston ma, our company caught up with forerunners in the bio...
.Merck & Co. is actually putting down $30 million in advance to acquire Yale spinout Modifi Biosc...
.Alpha-9 Oncology has raised a $175 thousand set C cycle to money its own clinical-stage radiopharma...
.Eye medication manufacturer Ocuphire Pharma is getting gene therapy programmer Piece Genetic makeup...
.Roche's persistent coughing course has faltered to a standstill. The drugmaker, which axed the cour...
.Gilead Sciences as well as Merck & Co. have guided their once-weekly HIV mix therapy past yet an...
.Lykos Therapeutics might have shed three-quarters of its own staff in the wake of the FDA's denial ...
.Septerna might be actually as yet to reveal "any type of relevant medical data," but the biotech ac...